OncoSec Medical Inc (ONCSQ)

[hschlauch]

What we know about TRACE is that it can be used effectively with any tissue type, meaning it can be used on heterogeneous visceral tumors where a local immune effect is needed. There simply are no other electroporation devices available on the market where DNA encoded plasmid agents can be delivered in this manner - they are all skin or muscular EP devices.

I have a strong gut feeling - based on Kevin Hollevoet's antibody investigations and recent patent filings - that ONCS is quietly pursuing a program to use their TRACE technology with multiple DNA-encoded checkpoint inhibitors. Again, this is just my opinion on where I think things could be heading in terms of collaborations with their TAP using TRACE technology. I don't know as though a big pharma would be involved, but nevertheless such a development program is going to attract a lot of attention if the approach demonstrates proof of principle.